Tonix Pharma’s Potential PTSD Cure: A Game-Changer? by Mark Eisenberg 12.02.2024 Tonix Pharmaceuticals receives FDA clearance for its OASIS trial, evaluating the efficacy of TNX-102 SL in treating acute stress reactions ...
AN2 Therapeutics Pauses Trial: Efficacy Concerns Rise by Mark Eisenberg 12.02.2024 AN2 Therapeutics voluntarily pauses enrollment in its epetraborole clinical trial due to lower efficacy. Safety is not a concern. The ...
Oppenheimer Trims Gilead Sciences Price Target by Mark Eisenberg 12.02.2024 Oppenheimer lowers price target on Gilead Sciences after Q4 earnings report and challenges in drug pipeline. Optimistic about prospects for ...
Atossa Genetics: Potential Breakthrough in Breast Cancer? by Lilu Anderson 12.02.2024 Biopharmaceutical company Atossa Genetics receives Buy rating from H.C. Wainwright, with a new price target of $4.00. The company's promising ...
Tomorrow’s Top Stock Picks: Winners & Losers Revealed by Mark Eisenberg 12.02.2024 Discover the winners and losers in the stock market, including tech giants Microsoft and NVIDIA, as well as underperformers Intel ...
GSK and Elegen Partner to Bolster R&D with DNA Tech by Lilu Anderson 24.01.2024 GSK and Elegen partner to develop new vaccines and medicines, harnessing Elegen's DNA manufacturing technology. Collaboration aims to expand genetic ...
Wall Street Analyzes Eli Lilly’s Promising Outlook by Terry Bingman 22.01.2024 Discover the promising future for investors in Eli Lilly and Company (NYSE: LLY), a leader in the biopharmaceutical industry, with ...
Trading on the Stock Exchange Kicks Off with Mixed Results by Mark Eisenberg 14.08.2023 Get the latest stock market update for top-performing companies like Intel, Microsoft, eBay, Cisco, and Kraft Heinz. Stay informed to ...